Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

Hepatology

Volumn 59, Issue 6, 2014, Pages 2426-

  Loustaud Ratti, Véronique ^a,b   Carrier, Paul ^a   Vong, Chanlina ^a   Essig, Marie ^c,d  

^a Fédération d'Hépatologie Service d'Hépato gastroentérologie   (France)

^b UMR 1092   (France)

^c Service de Néphrologie Dialyse Transplantation   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CIMETIDINE; CREATININE; DOLUTEGRAVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; TELAPREVIR; TRIMETHOPRIM;

GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FAILURE; LETTER; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION;

FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; OLIGOPEPTIDES; PROLINE; RENAL INSUFFICIENCY;

EID: 84901633154     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26730     Document Type: Letter

References (3)

1. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59:46-48.
2. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012;84:1096-1102.
3. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-743.